AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Bone marrow stromal antigen 2

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

We utilise our cutting-edge, exclusive workflow to develop focused libraries.

 Fig. 1. The sreening workflow of Receptor.AI

Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.

Several key aspects differentiate our library:

  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

Q10589

UPID:

BST2_HUMAN

Alternative names:

HM1.24 antigen; Tetherin

Alternative UPACC:

Q10589; A8K4Y4; Q53G07

Background:

Bone marrow stromal antigen 2, also known as Tetherin or HM1.24 antigen, is a pivotal IFN-induced antiviral host restriction factor. It blocks the release of various mammalian enveloped viruses by tethering nascent virions to infected cell membranes. This protein targets a wide array of viruses across diverse families, including HIV, HCV, EBOV, and SARS-CoV. Tetherin's ability to inhibit cell surface proteolytic activity and stimulate signaling pathways underscores its multifunctional role in viral restriction and immune response modulation.

Therapeutic significance:

Understanding the role of Bone marrow stromal antigen 2 could open doors to potential therapeutic strategies. Its broad antiviral activity and involvement in immune regulation make it a promising target for developing treatments against a wide range of viral infections and possibly modulating immune responses.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
No Spam. Cancel Anytime.